A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer
Objectives
This study aims to explore prediction of response to abemaciclib and predictors of intestinal toxicity in ER-positive metastatic breast cancer.
State
Enrolling by invitation
Subjects
ER-positive Metastatic Breast Cancer
Endpoints
･Time to Treatment Failure [ Time Frame: 2 years ]
･Incidence and severity of diarrhea [ Time Frame: Time Frame: 2 years ]
Trial Period
2020/12/14 - 2024/7/31
Lead Principal Investigator
Kosuke Kawaguchi
Target Sample Size
40
Regimen
-
Source of Funding
Eli Lilly Japan K.K.
Umin ID
Other
Institutions
Kyoto University Hospital(Kyoto)
Saitama Cancer Center(Saitama)
Sagara Hospital(Kagoshima)
Shinko Hospital(Hyogo)
Tenri Hospital(Nara)
Shiga General Hospital(Shiga)
Amagasaki General Medical Center(Hyogo)
Kitano Hospital(Osaka)
Japanese Red Cross Wakayama Medical Center(Wakayama)
Saitama Medical University International Medical Center(Saitama)
